These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22914438)

  • 1. Mechanistic basis for overcoming platinum resistance using copper chelating agents.
    Liang ZD; Long Y; Tsai WB; Fu S; Kurzrock R; Gagea-Iurascu M; Zhang F; Chen HH; Hennessy BT; Mills GB; Savaraj N; Kuo MT
    Mol Cancer Ther; 2012 Nov; 11(11):2483-94. PubMed ID: 22914438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming platinum drug resistance with copper-lowering agents.
    Chen HH; Kuo MT
    Anticancer Res; 2013 Oct; 33(10):4157-61. PubMed ID: 24122978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells.
    Ivy KD; Kaplan JH
    Mol Pharmacol; 2013 Jun; 83(6):1237-46. PubMed ID: 23543413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy.
    Chen HH; Chen WC; Liang ZD; Tsai WB; Long Y; Aiba I; Fu S; Broaddus R; Liu J; Feun LG; Savaraj N; Kuo MT
    Expert Opin Ther Targets; 2015; 19(10):1307-17. PubMed ID: 26004625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1.
    Chen HH; Song IS; Hossain A; Choi MK; Yamane Y; Liang ZD; Lu J; Wu LY; Siddik ZH; Klomp LW; Savaraj N; Kuo MT
    Mol Pharmacol; 2008 Sep; 74(3):697-704. PubMed ID: 18523133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulating Chemosensitivity of Tumors to Platinum-Based Antitumor Drugs by Transcriptional Regulation of Copper Homeostasis.
    Lai YH; Kuo C; Kuo MT; Chen HHW
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.
    Song IS; Savaraj N; Siddik ZH; Liu P; Wei Y; Wu CJ; Kuo MT
    Mol Cancer Ther; 2004 Dec; 3(12):1543-9. PubMed ID: 15634647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming platinum resistance through the use of a copper-lowering agent.
    Fu S; Naing A; Fu C; Kuo MT; Kurzrock R
    Mol Cancer Ther; 2012 Jun; 11(6):1221-5. PubMed ID: 22491798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy.
    Kuo MT; Fu S; Savaraj N; Chen HH
    Cancer Res; 2012 Sep; 72(18):4616-21. PubMed ID: 22962276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic comparison of human high-affinity copper transporter 1-mediated transport between copper ion and cisplatin.
    Liang ZD; Stockton D; Savaraj N; Tien Kuo M
    Mol Pharmacol; 2009 Oct; 76(4):843-53. PubMed ID: 19570948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines.
    Yoshizawa K; Nozaki S; Kitahara H; Ohara T; Kato K; Kawashiri S; Yamamoto E
    Oncol Rep; 2007 Oct; 18(4):987-91. PubMed ID: 17786364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts.
    Nakagawa T; Inoue Y; Kodama H; Yamazaki H; Kawai K; Suemizu H; Masuda R; Iwazaki M; Yamada S; Ueyama Y; Inoue H; Nakamura M
    Oncol Rep; 2008 Aug; 20(2):265-70. PubMed ID: 18636185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
    Mangala LS; Zuzel V; Schmandt R; Leshane ES; Halder JB; Armaiz-Pena GN; Spannuth WA; Tanaka T; Shahzad MM; Lin YG; Nick AM; Danes CG; Lee JW; Jennings NB; Vivas-Mejia PE; Wolf JK; Coleman RL; Siddik ZH; Lopez-Berestein G; Lutsenko S; Sood AK
    Clin Cancer Res; 2009 Jun; 15(11):3770-80. PubMed ID: 19470734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.
    Shang X; Lin X; Manorek G; Howell SB
    Mol Pharmacol; 2013 Jan; 83(1):85-94. PubMed ID: 23053666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of the high-affinity copper transporter (hCtr1) expression by cisplatin and heavy metals.
    Liang ZD; Long Y; Chen HH; Savaraj N; Kuo MT
    J Biol Inorg Chem; 2014 Jan; 19(1):17-27. PubMed ID: 24132751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1.
    Jandial DD; Farshchi-Heydari S; Larson CA; Elliott GI; Wrasidlo WJ; Howell SB
    Clin Cancer Res; 2009 Jan; 15(2):553-60. PubMed ID: 19147760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the methionines and histidines in the transmembrane domain of mammalian copper transporter 1 in the cellular accumulation of cisplatin.
    Larson CA; Adams PL; Blair BG; Safaei R; Howell SB
    Mol Pharmacol; 2010 Sep; 78(3):333-9. PubMed ID: 20519567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC).
    Li ZH; Qiu MZ; Zeng ZL; Luo HY; Wu WJ; Wang F; Wang ZQ; Zhang DS; Li YH; Xu RH
    J Transl Med; 2012 Feb; 10():21. PubMed ID: 22304828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional interactions of Cu-ATPase ATP7B with cisplatin and the role of ATP7B in the resistance of cells to the drug.
    Leonhardt K; Gebhardt R; Mössner J; Lutsenko S; Huster D
    J Biol Chem; 2009 Mar; 284(12):7793-802. PubMed ID: 19141620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo.
    Chen SJ; Kuo CC; Pan HY; Tsou TC; Yeh SC; Chang JY
    Biochem Pharmacol; 2015 May; 95(1):28-37. PubMed ID: 25801007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.